US4884452065
US4884452065
Zevra Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 676.38M EUR | 850.96M EUR | 550.95M EUR | 509.42M EUR |
Enterprise Value | 433.15M EUR | 707.14M EUR | 456.5M EUR | 510.22M EUR |
Valuation Multiples | ||||
Trailing P/E | 12.38x | 14.61x | 4.44x | 5.9x |
Forward P/E | 10.58x | -- | -- | -- |
Price to Sales | 4.97x | 6.25x | 4.51x | 5.92x |
Price to Book | 3.11x | 3.91x | 2.68x | 3.29x |
EV/Revenue | 3.18x | 5.2x | 3.73x | 5.93x |
EV/EBITDA | 10.68x | 13.94x | 20.09x | 51.35x |
Price to FCF (P/FCF) | 13.98x | 26.08x | 45.93x | 86.52x |
EV/FCF | 8.95x | 21.68x | 38.06x | 86.65x |
FCF Yield | 7.15% | 3.83% | 2.18% | 1.16% |